MDS-type abnormalities within myeloma signature karyotype (MM-MDS): Only 13% 1-year survival despite tandem transplants

British Journal of Haematology

Volumn 122, Issue 3, 2003, Pages 430-440

  Jacobson, Joth ^a   Barlogie, Bart ^b   Shaughnessy, John ^b   Drach, Johannes ^c   Tricot, Guido ^b   Fassas, Athanasios ^b   Zangari, Maurizio ^b   Giroux, Dori ^a   Crowley, John ^a   Hough, Aubrey ^b   Sawyer, Jeff ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cytogenetic abnormalities; MDS; Multiple myeloma

Indexed keywords

MELPHALAN;

ARTICLE; AUTOTRANSPLANTATION; CANCER RISK; CANCER SURVIVAL; CHROMOSOME 13; CHROMOSOME 20; CHROMOSOME 7; CHROMOSOME 9; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; TRISOMY;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHROMOSOME ABERRATIONS; CLUSTER ANALYSIS; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GENE DELETION; HUMANS; MELPHALAN; MONOSOMY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROMES; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SURVIVAL RATE; TRANSLOCATION, GENETIC; TRANSPLANTATION, AUTOLOGOUS; TRISOMY;

EID: 0043130490     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04455.x     Document Type: Article

References (39)

1. Avet-Loiseau, H., Facon, T., Grosbois, B., Magrangeas, F., Rapp, M.J., Harousseau, J.L., Minvielle, S. & Bataille, R. (2002) Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood, 99, 2185-2191.
2. Barlogie, B., Alexanian, R., Pershouse, M., Smallwood, L. & Smith, L. (1985) Cytoplasmic immunoglobulin content in multiple myeloma. Journal of Clinical Investigation, 76, 765-769.
3. Barlogie, B., Jagannath, S., Vesole, D.H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J. & Tricot, G. (1997) Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood, 89, 789-793.
4. Barlogie, B., Jagannath, S., Desikan, K.R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., Mehta, J., Anaissie, E., Dhodapkar, D., Naucke, S., Cromer, J., Sawyer, J., Epstein, J., Spoon, D., Ayers, D., Cheson, B. & Crowley, J. (1999) Total therapy for newly diagnosed multiple myeloma. Blood, 93, 55-65.
5. Barlogie, B., Tricot, G., Shaughnessy, J., Jacobson, J., Eddlemon, P., McCoy, J., Anaissie, E., Zangari, M., Fassas, A. & Sawyer, J. (2002) Cytogenetic abnormalities at diagnosis or on serial follow-up are incompatible with durable disease control in multiple myeloma even after Total Therapy I. Blood, 100, 369a.
6. Boccadorro, M., Massaia, M., Dianzani, U. & Pileri, A. (1987) Multiple myeloma: biological and clinical significance of bone marrow plasma cell labeling index. Haematologica, 72, 171-175.
7. Chesi, M., Bergsagel, P.L., Brents, L.A., Smith, C.M., Gerhard, D.S. & Kuehl, W.M. (1996) Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood, 88, 674-681.
8. Chesi, M., Nardini, E., Brents, L.A., Schrock, E., Ried, T., Kuehl, W.M. & Bergsagel, P.L. (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nature Genetics, 16, 260-264.
9. Chesi, M., Nardini, E., Lim, R.S., Smith, K.D., Kuehl, W.M. & Bergsagel, P.L. (1998a) The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood, 92, 3025-3034.
10. Chesi, M., Bergsagel, P.L., Shonukan, O.O., Martelli, M.L., Brents, L.A., Chen, T., Schrock, E., Ried, T. & Kuehl, W.M. (1998b) Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood, 91, 4457-4463.
11. Cox, D.R. (1972) Regression models and life-tables. Journal of the Royal Statistical Society, Series B, 34, 187-220.
12. Desikan, R., Barlogie, B., Sawyer, J., Ayers, D., Tricot, G., Badros, A., Zangari, M., Munshi, N.C., Anaissie, E., Spoon, D., Siegel, D., Jagannath, S., Vesole, D., Epstein, J., Shaughnessy, J., Fassas, A., Lim, S., Roberson, P. & Crowley, J. (2000) Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood, 95, 4008-4010.
13. Dewald, G.W., Kyle, R.A., Hicks, G.A. & Greipp, P.R. (1985) The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood, 66, 380-390.
14. Drach, J., Schuster, J., Nowotny, H., Angerler, J., Rosenthal, F., Fiegl, M., Rothermundt, C., Gsur, A., Jager, U. & Heinz, R. (1995) Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Research, 55, 3854-3859.
15. Everitt, B. (1980) Cluster Analysis, 2nd edn. Halsted, New York.
16. Fassas, A., Spencer, T., Sawyer, J., Zangari, M., Lee, C.K., Anaissie, E., Muwalla, F., Morris, C., Barlogie, B. & Tricot, G. (2002) Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. British Journal of Haematology, 118, 1-7.
17. Gould, J., Alexanian, R., Goodacre, A., Pathak, S., Hecht, B. & Barlogie, B. (1988) Plasma cell karyotype in multiple myeloma. Blood, 71, 453-456.
18. Greipp, P.R., Katzmann, J.A., O'Fallon, W.M. & Kyle, R.A. (1988) Value of β2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood, 72, 219-223.
19. Greipp, P.R., Lust, J.A., O'Fallon, W.M., Katzmann, J.A., Witzig, T.E. & Kyle, R.A. (1993) Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood, 81, 3382-3387.
20. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation for incomplete observations. Journal of the American Statistical Association, 53, 457-481.
21. Klausner, R. (2002) The fabric of cancer cell biology: weaving together the strands. Cancer Cell, 1, 3-10.
22. Latreille, J., Barlogie, B., Johnston, D., Drewinko, B. & Alexanian, R. (1982) Ploidy and proliferative characteristics in monoclonal gammopathies. Blood, 59, 43-51.
23. Mantel, N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports, 50, 163-170.
24. Moreau, P., Facon, T., Leleu, Z., Morineau, N., Huughe, P., Harousseau, J., Bataille, R. & Herve, A. for the Intergroupe Francophone du Myeloma (2002) Recurrent 14q32 translocations determine the prognosis of multiple myeloma especially in patients receiving intensive chemotherapy. Blood, 100, 1579-1583.
25. Rao, P.H., Cigudosa, J., Ning, Y., Calasanz, M.J., Iida, S., Tagawa, S., Michaeli, J., Klein, B., Dalla-Favera, R., Jhanwar, S.C., Ried, T. & Chaganti, R.S. (1998) Karyotypic complexity of multiple myeloma defined by multicolor spectral karyotyping (SKY). Blood, 92, 1743-1748.
26. Sawyer, J.R., Waldron, J.A., Jagannath, S. & Barlogie, B. (1995) Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genetics and Cytogenetics, 82, 41-49.
27. Sawyer, J.R., Tricot, G., Mattox, S., Jagannath, S. & Barlogie, B. (1998a) Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of heterochromatin. Blood, 91, 1732-1741.
28. Sawyer, J., Drach, J., Ayers, D., Desikan, R., Munshi, N., Siegel, D., Mehta, J., Singhal, S., Anaissie, E. & Barlogie, B. (1998b) Adverse prognosis in multiple myeloma (MM) in the presence of MDS-associated cytogenetic (CG) abnormalities within a MM typical karyotype. Blood, 92, 399a.
29. Sawyer, J.R., Lukacs, J.L., Munshi, N., Desikan, K.R., Singhal, S., Mehta, J., Siegel, D., Shaughnessy, J. & Barlogie, B. (1998c) Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood, 92, 4269-4278.
30. Sawyer, J.R., Lukacs, J.L., Munshi, N., Tricot, G., Shaughnessy, J. & Barlogie, B. (2001) Multicolor spectral karyotyping identifies new translocations and a recurring pathway for chromosome instability in multiple myeloma. British Journal of Haematology, 112, 167-174.
31. Seong, C., Delasalle, K., Hayes, K., Weber, D., Dimopoulos, M., Swantkowski, J., Huh, Y., Glassman, A., Champlin, R. & Alexanian, R. (1998) Prognostic value of cytogenetics in multiple myeloma. British Journal of Haematology, 101, 189-194.
32. Shaughnessy, J., Zhan, F., Kordsmeier, B., Randolph, C., McCatlain, K. & Barlogie, B. (2002) Gene expression profiling after short term in-vivo treatment identifies potential mechanisms of action of current drugs used to treat multiple myeloma. Blood, 100, 781a.
33. Shaughnessy, J., Barlogie, B., Sawyer, J., McCoy, J., Fassas, A., Zhan, F., Bumm, K., Epstein, J., Anaissie, E., Jagannath, S., Vesole, D., Siegel, D., Desikan, R., Munshi, N., Badros, A., Tian, E., Zangari, M., Jacobson, J., Crowley, J. & Tricot, G. (2003a) Continuous absence of metaphase-defined cytogenetic abnormalities especially of chromosome 13 and hypodiploidy assures long-term survival in multiple myeloma treated with total therapy I: interpretation in the context of global gene expression. Blood, pre-published online January 2003.
34. Shaughnessy, J., Tian, E., Sawyer, J., McCoy, J., Tricot, G., Jacobson, J., Anaissie, E., Zangari, A., Fassas, A., Muwalla, F., Morris, C. & Barlogie, B. (2003b) Prognostic impact of cytogenetic and interphase FISH defined chromosome 13 deletion in multiple myeloma: early results of Total Therapy II. British Journal of Haematology, 120, 44-52.
35. Smadja, N., Bastard, C., Brigaudeau, C., Leroux, D. & Fruchart, C. for the Groupe Francais de Cytogenetique Hematologique (2001) Hypodiploidy is a major prognostic factor in multiple myeloma. Blood, 98, 2229-2238.
36. Tabernero, D., San Miguel, J.F., Garcia-Sanz, M., Najera, L., Garcia-Isidoro, M., Perez-Simon, J.A., Gonzalez, M., Wiegant, J., Raap, A.K. & Orfao, A. (1996) Incidence of chromosome numerical changes in multiple myeloma: fluorescence in situ hybridization analysis using 15 chromosome-specific probes. American Journal of Pathology, 149, 153-161.
37. Tricot, G., Sawyer, J., Jagannath, S., Bracy, D., Mattox, S., Vesole, D., Naucke, S. & Barlogie, B. (1995) Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood, 86, 4250-4256.
38. Zandecki, M., Lai, J.L. & Facon, T. (1996) Multiple myeloma: almost all patients are cytogenetically abnormal. British Journal of Haematology, 94, 217-227.
39. Zhan, F., Hardin, J., Kordsmeier, B., Bumm, K., Zheng, M., Tian, E., Sanderson, R., Yang, Y., Wilson, C., Zangari, M., Anaissie, E., Morris, C., Muwalla, F., van Rhee, F., Fassas, A., Crowley, J., Tricot, G., Barlogie, B. & Shaughnessy, S. (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance and normal bone marrow plasma cells. Blood, 99, 1745-1757.